MX2017003941A - Composicion acuosa. - Google Patents

Composicion acuosa.

Info

Publication number
MX2017003941A
MX2017003941A MX2017003941A MX2017003941A MX2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A
Authority
MX
Mexico
Prior art keywords
aqueous composition
formula
solvate
salt
halogen atom
Prior art date
Application number
MX2017003941A
Other languages
English (en)
Inventor
Sugimoto Shin
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2017003941A publication Critical patent/MX2017003941A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una composición acuosa que tiene un excelente efecto antiséptico; una composición acuosa que comprende un compuesto representado por la Fórmula (1), en donde X representa un átomo de halógeno, o una sal del mismo, o un solvato del compuesto o la sal del mismo, y un agente tensoactivo de amonio cuaternario. (ver Fórmula).
MX2017003941A 2014-09-25 2015-09-25 Composicion acuosa. MX2017003941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014194679 2014-09-25
PCT/JP2015/077013 WO2016047719A1 (ja) 2014-09-25 2015-09-25 水性組成物

Publications (1)

Publication Number Publication Date
MX2017003941A true MX2017003941A (es) 2017-06-26

Family

ID=55581238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003941A MX2017003941A (es) 2014-09-25 2015-09-25 Composicion acuosa.

Country Status (17)

Country Link
US (1) US10376523B2 (es)
EP (1) EP3199160B1 (es)
JP (5) JP6236166B2 (es)
KR (1) KR101830588B1 (es)
CN (1) CN106714806B (es)
BR (1) BR112017006150A2 (es)
CA (1) CA2962562A1 (es)
DK (1) DK3199160T3 (es)
ES (1) ES2779314T3 (es)
HU (1) HUE048790T2 (es)
MX (1) MX2017003941A (es)
MY (1) MY177032A (es)
PL (1) PL3199160T3 (es)
PT (1) PT3199160T (es)
SG (1) SG11201702202UA (es)
TW (1) TWI668215B (es)
WO (1) WO2016047719A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3199161T3 (da) * 2014-09-25 2022-01-03 Kowa Co Farmaceutisk præparat
CN113262226B (zh) * 2021-04-19 2023-05-16 杭州市第一人民医院 利舒地尔在制备细菌感染治疗药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
WO2005108446A1 (ja) 2004-05-07 2005-11-17 Asahi Glass Company, Limited 含フッ素共重合体とその製造方法およびそれを含むレジスト組成物
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US20060142270A1 (en) 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. ４－ブロモイソキノリン誘導体及びこれを含有する医薬
JP2006348028A (ja) * 2005-05-19 2006-12-28 Kowa Co 緑内障予防又は治療剤
EP1902731B1 (en) * 2005-06-21 2013-04-10 Kowa Company, Ltd. Preventive or remedy for glaucoma
EP1905452B1 (en) * 2005-07-12 2013-06-19 Kowa Company, Ltd. Agent for prevention or treatment of glaucoma
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US20080064681A1 (en) * 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
KR102074020B1 (ko) 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
CN105050600B (zh) 2013-04-24 2018-09-28 国立大学法人九州大学 眼底疾病治疗剂

Also Published As

Publication number Publication date
JP2021143179A (ja) 2021-09-24
US10376523B2 (en) 2019-08-13
TW201619147A (zh) 2016-06-01
EP3199160B1 (en) 2020-03-11
KR20170063565A (ko) 2017-06-08
CA2962562A1 (en) 2016-03-31
PL3199160T3 (pl) 2020-07-27
JPWO2016047719A1 (ja) 2017-06-29
BR112017006150A2 (pt) 2017-12-12
PT3199160T (pt) 2020-04-08
MY177032A (en) 2020-09-02
JP6236166B2 (ja) 2017-11-22
CN106714806A (zh) 2017-05-24
JP2019194273A (ja) 2019-11-07
EP3199160A4 (en) 2018-04-25
TWI668215B (zh) 2019-08-11
KR101830588B1 (ko) 2018-02-20
US20170290841A1 (en) 2017-10-12
ES2779314T3 (es) 2020-08-14
WO2016047719A1 (ja) 2016-03-31
JP2023052791A (ja) 2023-04-12
HUE048790T2 (hu) 2020-09-28
SG11201702202UA (en) 2017-04-27
CN106714806B (zh) 2020-03-03
EP3199160A1 (en) 2017-08-02
JP2018012736A (ja) 2018-01-25
DK3199160T3 (da) 2020-04-20

Similar Documents

Publication Publication Date Title
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12016500169A1 (en) Polymorph of syk inhibitors
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
EA201692219A1 (ru) Способы получения противовирусных соединений
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MX2018007418A (es) Compuestos de benzamida y sus usos como herbicidas.
PH12019501362A1 (en) Polymorphs
MX2016014197A (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
MY178881A (en) Novel aqueous composition
TW201613603A (en) Pharmaceutical preparation
MX2018016290A (es) Agente antidesgaste.
MY178880A (en) Composition
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MY178370A (en) Aqueous composition
MA39824A (fr) Composés azole amido-substitués
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2017003941A (es) Composicion acuosa.
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
MX2018006387A (es) Composicion antimicrobiana de limpieza.
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
UA98157U (uk) Метиламонієва сіль 2-(4-аміно-5-(4-третбутилфеніл)-4н-1,2,4-триазол-3-ілтіо)ацетатної кислоти, що проявляє протимікробну активність